Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11130MR)

This product GTTS-WQ11130MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Dermatomyositis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11130MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2708MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ5550MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ15832MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ9001MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ12432MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ2192MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ2553MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ2268MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW